Industry News
Pricing changes, regulatory decisions, coverage shifts and market exits — dated to the development, not to when we wrote it.
25 dated developments affecting what tirzepatide costs and who sells it. Most recent: Generic semaglutide launches abroad; US patients wait until 2031 (2026-08-06).
Every item names its source and closes on what it changes for someone paying for treatment. Where a story is still moving — a proposed rule, an ongoing enforcement matter — the item says so rather than implying it is settled.
All-in monthly cost at 10 mg
Every story, newest first
Generic semaglutide launches abroad; US patients wait until 2031
Indian generics started near $8 a month in March. The FDA has tentatively approved a US version that cannot le…
Lilly Q2: volume up 60%, realised prices down 13%
Zepbound revenue grew well below volume, which means the average price actually paid for branded tirzepatide i…
Medicare GLP-1 Bridge reported as an inflection point in month one
Access expanded to roughly 20 million eligible beneficiaries, with prior authorisation reportedly running smoo…
We re-checked sixteen compounded prices at source. Fifteen were wrong
Every correction moved the price upward, which means published cheapest figures are systematically low.…
Retatrutide reaches 30.3% weight loss in Phase 3
The triple agonist clears its pivotal obesity programme. Filing is planned for Q1 2027, which puts a prescript…
Three ownership structures, three risk profiles
Owned pharmacy, single contracted partner, or several named partners. The difference only becomes visible when…
Ro and WeightWatchers Clinic now carry brand only
Two of the largest consumer platforms stopped selling compounded tirzepatide during 2026, with membership bill…
Summer shipping is the season for cold-chain failures
Warm arrivals cluster in the hottest months, and most programmes put the judgement call on the patient.…
Microdose protocols spread, and they are not comparable to standard dosing
Fractional-dose plans at lower prices do not map onto the 2.5–15 mg ladder every comparison uses.…
FDA proposes excluding tirzepatide from the 503B bulks list
If finalised, outsourcing facilities would lose a pathway for compounding at scale.…
Membership stacking spreads: the advertised price is increasingly not the price
Several programmes now split the charge into medication plus a mandatory platform fee.…
More employers drop weight-management GLP-1 coverage at renewal
Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.…
Alerts continue on counterfeit product and research-labelled peptide
Two different problems, one outcome: an unverified substance in a syringe.…
State action against a telehealth company's own compounding pharmacy
When the platform and the pharmacy are the same business, a regulatory action lands directly on patients with …
First-month promotional rates published as ongoing prices
A recurring error across round-ups, and the likely origin of several wrong figures.…
First oral GLP-1 for weight loss approved, priced from $149
A daily tablet reaches the market at a fraction of injectable brand pricing, with a smaller effect size.…
States gain the option to expand GLP-1 access through Medicaid
A route that did not exist for the lowest-income patients — but optional, so it will be a patchwork.…
Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglutide.…
Zepbound KwikPen reaches self-pay pricing and retail pickup
The metered pen joins the vial at the same tiers, removing the syringe objection from the brand route.…
Lilly cuts Zepbound self-pay pricing to $299–$449
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most coverage omits.…
FDA issues warning letters to compounded GLP-1 marketers
Several telehealth companies were cited over labelling and marketing claims, not over patient harm.…
Prepaid plans are where the money gets stuck
Multi-month discounts are real, and so is the fact that compounded medication is generally not refundable once…
A year after the shortage was declared over, the market has restructured
Scope narrowed and large platforms exited, but patient-specific compounding continues.…
Semaglutide approved for MASH with moderate to advanced fibrosis
The first GLP-1 with an FDA liver indication — and a coverage route that weight management is not.…
Zepbound approved for obstructive sleep apnoea
A discrete diagnosis with an approved indication is a stronger prior-authorisation argument than a BMI thresho…
Reading this alongside the rest of the site
Pricing pages isolate one component. Provider reviews carry the whole record for one programme. Comparisons run two side by side at every dose. The rankings sort the same dataset on different questions. None is the whole picture and none is meant to be.
If you read one other page, make it how to verify a pharmacy. Price is the easiest thing to compare and rarely the thing that goes wrong.
What we would need to change our mind
A programme publishing a figure at a dose tier currently blank. A named dispensing pharmacy with a checkable licence. A pricing model changing in either direction. A regulatory action. Or a correction from a reader with a source we can open.
All five are logged with the date they landed, on the change log and in the dataset. Prices here were captured 2026-08-05.
What this site will not do
Publish an estimated price for a programme that does not publish one. Rank a programme higher because it pays. Present a compounded preparation as equivalent to an approved product. Or carry a figure without the date it was captured.
Those four rules cost us pages, rankings and revenue, and they are the only reason a reader has to prefer this to a round-up assembled in an afternoon. A price without its date is not a fact, and a comparison built from undated prices is not a comparison.
Who this site is not for
Anyone with coverage under a documented indication, who should use it rather than read a cash comparison. Anyone looking for a source without a prescription, which this site will not help with. And anyone wanting a single confident recommendation, because the honest answer depends on your dose, your coverage and your tolerance for commitment.
If you want the short version anyway: price the dose you will hold, add every fee, verify the pharmacy, and avoid long prepaid terms until you have tolerated a maintenance dose for a cycle.
The question worth asking before the price question
Whether you have a covered indication. Tirzepatide is approved for chronic weight management and, as Mounjaro, for type 2 diabetes; obstructive sleep apnoea in adults with obesity is an additional route. A covered prescription under a documented indication beats every cash route on this site, frequently by an order of magnitude.
Most people do this backwards: compare cash prices, enrol, then discover an indication they already qualified for. Establishing coverage first costs a phone call and can save four figures a year, which is more than any comparison table on this site will save you.
Reading a price like a clinician would
A clinician deciding whether a programme is workable asks three questions a price comparison usually skips. Can this patient stay on it long enough to reach a maintenance dose? Is the supply reliable enough that titration will not be interrupted? And is the prescriber reachable when the fourth-week nausea arrives?
Each maps to something checkable before enrolling. Long prepaid terms answer the first badly if money is tight. A single owned dispensing facility answers the second worse than several named partner pharmacies, because a programme with one supply route cannot reroute your prescription. And the care model answers the third: asynchronous messaging is adequate for most titration questions and inadequate for a few.
None of that appears in an advertised price, and all of it decides whether the price you chose is the price you end up paying.
What the GIP arm may be doing
GIP receptor agonism is the pharmacological difference between tirzepatide and the GLP-1-only agents, and its contribution is still being characterised. Proposed mechanisms include effects on adipose tissue insulin sensitivity, on central appetite pathways distinct from the GLP-1 route, and on the tolerability of GLP-1 agonism itself, which would allow effective exposure at doses that would otherwise be poorly tolerated.
This is an area of active research rather than settled science, and anyone stating the mechanism confidently is ahead of the literature. What is established is the outcome difference in the head-to-head trial; the explanation for it is not fully resolved.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.